Andrew P Demidowich1,2, Jordan A Levine1, Ginikanwa I Onyekaba1, Shahzaib M Khan1, Kong Y Chen3, Sheila M Brady1, Miranda M Broadney1,2, Jack A Yanovski1. 1. Section on Growth and Obesity, Division of Intramural Research (DIR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, Maryland. 2. Office of the Clinical Director, NICHD, NIH, Bethesda, Maryland. 3. Energy Metabolism Section, Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes, Digestive and Kidney Diseases, NIH, Bethesda, Maryland.
Abstract
AIM: To evaluate the efficacy and safety of colchicine for improving metabolic and inflammatory outcomes in people with obesity and metabolic syndrome (MetS). MATERIALS AND METHODS: Adults with obesity and MetS, but who did not have diabetes, were randomized to colchicine 0.6 mg or placebo capsules twice daily for 3 months. The primary outcome was change in insulin sensitivity (SI ) as estimated by insulin-modified frequently sampled intravenous glucose tolerance tests. Secondary outcomes included changes in other metabolic variables and inflammatory markers. RESULTS: Of 40 participants randomized (21colchicine, 19 placebo), 37 completed the trial. Compared with placebo, colchicine significantly reduced C-reactive protein (P <0.005), erythrocyte sedimentation rate (P <0.01), white blood cell count (P <0.005), and absolute neutrophil count (P <0.001). Change in SI was not significantly different between colchicine and placebo arms (difference: +0.21 × 10-5 ; CI -1.70 to +2.13 × 10-5 min-1 mU-1 mL; P = 0.82). However, changes in some secondary outcomes, including homeostatic model assessment of insulin resistance (P = 0.0499), fasting insulin (P = 0.07) and glucose effectiveness (P = 0.08), suggested metabolic improvements in the colchicine versus placebo group. Adverse events were generally mild and similar in both groups. CONCLUSIONS: This pilot study found colchicine significantly improved obesity-associated inflammatory variables and showed a good safety profile among adults with obesity and MetS who did not have diabetes. These results suggest a larger, adequately powered study should be conducted to determine whether colchicine improves insulin resistance and other measures of metabolic health in at-risk individuals. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.
RCT Entities:
AIM: To evaluate the efficacy and safety of colchicine for improving metabolic and inflammatory outcomes in people with obesity and metabolic syndrome (MetS). MATERIALS AND METHODS: Adults with obesity and MetS, but who did not have diabetes, were randomized to colchicine 0.6 mg or placebo capsules twice daily for 3 months. The primary outcome was change in insulin sensitivity (SI ) as estimated by insulin-modified frequently sampled intravenous glucose tolerance tests. Secondary outcomes included changes in other metabolic variables and inflammatory markers. RESULTS: Of 40 participants randomized (21 colchicine, 19 placebo), 37 completed the trial. Compared with placebo, colchicine significantly reduced C-reactive protein (P <0.005), erythrocyte sedimentation rate (P <0.01), white blood cell count (P <0.005), and absolute neutrophil count (P <0.001). Change in SI was not significantly different between colchicine and placebo arms (difference: +0.21 × 10-5 ; CI -1.70 to +2.13 × 10-5 min-1 mU-1 mL; P = 0.82). However, changes in some secondary outcomes, including homeostatic model assessment of insulin resistance (P = 0.0499), fasting insulin (P = 0.07) and glucose effectiveness (P = 0.08), suggested metabolic improvements in the colchicine versus placebo group. Adverse events were generally mild and similar in both groups. CONCLUSIONS: This pilot study found colchicine significantly improved obesity-associated inflammatory variables and showed a good safety profile among adults with obesity and MetS who did not have diabetes. These results suggest a larger, adequately powered study should be conducted to determine whether colchicine improves insulin resistance and other measures of metabolic health in at-risk individuals. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Paul M Ridker; Brendan M Everett; Tom Thuren; Jean G MacFadyen; William H Chang; Christie Ballantyne; Francisco Fonseca; Jose Nicolau; Wolfgang Koenig; Stefan D Anker; John J P Kastelein; Jan H Cornel; Prem Pais; Daniel Pella; Jacques Genest; Renata Cifkova; Alberto Lorenzatti; Tamas Forster; Zhanna Kobalava; Luminita Vida-Simiti; Marcus Flather; Hiroaki Shimokawa; Hisao Ogawa; Mikael Dellborg; Paulo R F Rossi; Roland P T Troquay; Peter Libby; Robert J Glynn Journal: N Engl J Med Date: 2017-08-27 Impact factor: 91.245
Authors: Rinke Stienstra; Leo A B Joosten; Tim Koenen; Berry van Tits; Janna A van Diepen; Sjoerd A A van den Berg; Patrick C N Rensen; Peter J Voshol; Giamilla Fantuzzi; Anneke Hijmans; Sander Kersten; Michael Müller; Wim B van den Berg; Nico van Rooijen; Martin Wabitsch; Bart-Jan Kullberg; Jos W M van der Meer; Thirumala Kanneganti; Cees J Tack; Mihai G Netea Journal: Cell Metab Date: 2010-12-01 Impact factor: 27.287
Authors: R L Anderson; R F Hamman; P J Savage; M F Saad; A Laws; W W Kades; R E Sands; W Cefalu Journal: Am J Epidemiol Date: 1995-10-01 Impact factor: 4.897
Authors: M F Saad; R L Anderson; A Laws; R M Watanabe; W W Kades; Y D Chen; R E Sands; D Pei; P J Savage; R N Bergman Journal: Diabetes Date: 1994-09 Impact factor: 9.461
Authors: Claus M Larsen; Mirjam Faulenbach; Allan Vaag; Aage Vølund; Jan A Ehses; Burkhardt Seifert; Thomas Mandrup-Poulsen; Marc Y Donath Journal: N Engl J Med Date: 2007-04-12 Impact factor: 91.245
Authors: Andrew P Demidowich; Anna Wolska; Sierra R Wilson; Jordan A Levine; Alexander V Sorokin; Sheila M Brady; Alan T Remaley; Jack A Yanovski Journal: J Clin Lipidol Date: 2019-10-22 Impact factor: 4.766
Authors: Jordan A Levine; Zahra Sarrafan-Chaharsoughi; Tushar P Patel; Sheila M Brady; K Karthik Chivukula; Emily Miller; Jung Min Han; Vipul Periwal; Anna Wolska; Alan T Remaley; Pradeep K Dagur; Angelique Biancotto; Ashley Babyak; Giovanna Fantoni; Jack A Yanovski; Andrew P Demidowich Journal: Obesity (Silver Spring) Date: 2022-01-03 Impact factor: 9.298
Authors: Alberto Cecconi; Pablo Martinez-Vives; Alberto Vera; Cristina Lavilla Olleros; Ana Barrios; Eva Fonseca Aizpuru; Pilar Roquero; Susana Hernandez Muñiz; Maria Jose Olivera; Marianela Ciudad; Ruben Pampin Sanchez; Rosa Fernandez-Madera Martínez; Azucena Bautista-Hernández; Elena García Castillo; Gorane Iturricastillo; Elena Ávalos; Diana Prada Cotado; Alvaro Alejandre de Oña; Eduardo Fernandez Carracedo; Ana Marcos-Jimenez; Ancor Sanz-Garcia; Aranzazu Alfranca; Maurizio Cecconi; Hortensia de La Fuente; Maria Angeles Sanz de Benito; Paloma Caballero; Francisco Sanchez-Madrid; Julio Ancochea; Carmen Suarez; Luis Jesus Jimenez-Borreguero; Fernando Alfonso Journal: Sci Rep Date: 2022-06-02 Impact factor: 4.996
Authors: Jordan A Levine; Jung Min Han; Anna Wolska; Sierra R Wilson; Tushar P Patel; Alan T Remaley; Vipul Periwal; Jack A Yanovski; Andrew P Demidowich Journal: J Clin Lipidol Date: 2020-08-04 Impact factor: 4.766
Authors: Sarah Stewart; Kevin Chih Kai Yang; Kate Atkins; Nicola Dalbeth; Philip C Robinson Journal: Arthritis Res Ther Date: 2020-02-13 Impact factor: 5.156
Authors: Andrew P Demidowich; Jordan A Levine; Sheila M Brady; Cheryl D Johnson; Steven J Soldin; Jack A Yanovski Journal: Diabetes Obes Metab Date: 2020-04-20 Impact factor: 6.408
Authors: Chen-Chih Chu; Yong-Chen Chen; Ming-Hsun Lin; Wen-Tung Wu; Feng-Cheng Liu; Hsiang-Cheng Chen; Yu-Ching Chou; Chien-An Sun Journal: Int J Environ Res Public Health Date: 2022-03-14 Impact factor: 3.390